1-9 of 9
Hiroyoshi Nishikawa
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)

Hitomi S. Okuma, Keisuke Watanabe, Kenji Tsuchihashi, Ryunosuke Machida, Ryo Sadachi, Akihiro Hirakawa, Hiroshi Ariyama, Masashi Kanai, Masahisa Kamikura, Kenta Anjo, Akari Hiramitsu, Shigeki Sekine, Natsuko Okita, Hiroyuki Mano, Hiroyoshi Nishikawa, Kenichi Nakamura, Kan Yonemori
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5079–5086.
https://doi.org/10.1158/1078-0432.CCR-23-1807
Published: 15 December 2023
View article titled, Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial)
Open the PDF for Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial) in another window
Includes: Supplementary data
Journal Articles

Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials

Hiroki Yukami, Akihito Kawazoe, Yi-Tzu Lin, Shohei Koyama, Shota Fukuoka, Hiroki Hara, Naoki Takahashi, Takashi Kojima, Masako Asayama, Takako Yoshii, Hideaki Bando, Daisuke Kotani, Yoshiaki Nakamura, Yasutoshi Kuboki, Saori Mishima, Masashi Wakabayashi, Takeshi Kuwata, Masahiro Goto, Kazuhide Higuchi, Takayuki Yoshino, Toshihiko Doi, Hiroyoshi Nishikawa, Kohei Shitara
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3480–3488.
https://doi.org/10.1158/1078-0432.CCR-22-0630
Published: 15 August 2022
View article titled, Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials
Open the PDF for Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer

Hideaki Bando, Yuichiro Tsukada, Koji Inamori, Yosuke Togashi, Shohei Koyama, Daisuke Kotani, Shota Fukuoka, Satoshi Yuki, Yoshito Komatsu, Shigenori Homma, Akinobu Taketomi, Mamoru Uemura, Takeshi Kato, Makoto Fukui, Masashi Wakabayashi, Naoki Nakamura, Motohiro Kojima, Hiroshi Kawachi, Richard Kirsch, Tsutomu Yoshida, Yutaka Suzuki, Akihiro Sato, Hiroyoshi Nishikawa, Masaaki Ito, Takayuki Yoshino
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1136–1146.
https://doi.org/10.1158/1078-0432.CCR-21-3213
Published: 15 March 2022
View article titled, Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer
Open the PDF for Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer in another window
Includes: Supplementary data
Journal Articles

TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)

Akihito Kawazoe, Kota Itahashi, Noboru Yamamoto, Daisuke Kotani, Yasutoshi Kuboki, Hiroya Taniguchi, Kenichi Harano, Yoichi Naito, Mitsuko Suzuki, Miki Fukutani, Tsukiko Higuchi, Takashi Ikeno, Masashi Wakabayashi, Akihiro Sato, Shohei Koyama, Hiroyoshi Nishikawa, Kohei Shitara
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6709–6715.
https://doi.org/10.1158/1078-0432.CCR-21-1929
Published: 15 December 2021
View article titled, TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704)
Open the PDF for TAS-116 (Pimitespib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704) in another window
Includes: Supplementary data
Journal Articles

Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)

Akihito Kawazoe, Yasutoshi Kuboki, Eiji Shinozaki, Hiroki Hara, Tomohiro Nishina, Yoshito Komatsu, Satoshi Yuki, Masashi Wakabayashi, Shogo Nomura, Akihiro Sato, Takeshi Kuwata, Masahito Kawazu, Hiroyuki Mano, Yosuke Togashi, Hiroyoshi Nishikawa, Takayuki Yoshino
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (22): 5887–5894.
https://doi.org/10.1158/1078-0432.CCR-20-1803
Published: 13 November 2020
View article titled, Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)
Open the PDF for Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial) in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors

Toshihiko Doi, Kei Muro, Hiroshi Ishii, Terufumi Kato, Takahiro Tsushima, Mitsuhiro Takenoyama, Satoshi Oizumi, Kazuto Gemmoto, Hideaki Suna, Kouki Enokitani, Tetsuyoshi Kawakami, Hiroyoshi Nishikawa, Noboru Yamamoto
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (22): 6614–6622.
https://doi.org/10.1158/1078-0432.CCR-19-1090
Published: 15 November 2019
View article titled, A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
Open the PDF for A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity

Tokiyoshi Tanegashima, Yosuke Togashi, Koichi Azuma, Akihiko Kawahara, Ko Ideguchi, Daisuke Sugiyama, Fumio Kinoshita, Jun Akiba, Eiji Kashiwagi, Ario Takeuchi, Takuma Irie, Katsunori Tatsugami, Tomoaki Hoshino, Masatoshi Eto, Hiroyoshi Nishikawa
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (15): 4808–4819.
https://doi.org/10.1158/1078-0432.CCR-18-3991
Published: 01 August 2019
View article titled, Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
Open the PDF for Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity in another window
Includes: Supplementary data
Journal Articles

Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients

Koji Kurose, Yoshihiro Ohue, Hisashi Wada, Shinsuke Iida, Takashi Ishida, Takashi Kojima, Toshihiko Doi, Susumu Suzuki, Midori Isobe, Takeru Funakoshi, Kazuhiro Kakimi, Hiroyoshi Nishikawa, Heiichiro Udono, Mikio Oka, Ryuzo Ueda, Eiichi Nakayama
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (19): 4327–4336.
https://doi.org/10.1158/1078-0432.CCR-15-0357
Published: 30 September 2015
View article titled, Phase Ia Study of FoxP3<sup>+</sup> CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
Open the PDF for Phase Ia Study of FoxP3<sup>+</sup> CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals

Jun Mitsui, Hiroyoshi Nishikawa, Daisuke Muraoka, Linan Wang, Takuro Noguchi, Eiichi Sato, Satoshi Kondo, James P. Allison, Shimon Sakaguchi, Lloyd J. Old, Takuma Kato, Hiroshi Shiku
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (10): 2781–2791.
https://doi.org/10.1158/1078-0432.CCR-09-3243
Published: 13 May 2010
View article titled, Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
Open the PDF for Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals in another window
Includes: Supplementary data